Production (Stage)
Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | -- | -- | 0.00% | -80.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | -- | -- | 0.00% | -80.00% |
| Cost of Revenue | -96.16% | -5.52% | 60.86% | 56.63% | 7.91% |
| Gross Profit | 112.60% | 5.52% | -60.68% | -64.62% | -333.98% |
| SG&A Expenses | 14.90% | 56.01% | -1.10% | -3.29% | -21.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -78.27% | 8.11% | 45.70% | 40.03% | 1.69% |
| Operating Income | 89.20% | -8.11% | -45.56% | -43.95% | -136.55% |
| Income Before Tax | 89.42% | -83.75% | -6.66% | -344.76% | -685.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 89.42% | -83.75% | -6.66% | -344.84% | -685.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.42% | -83.75% | -6.66% | -344.84% | -685.00% |
| EBIT | 89.20% | -8.11% | -45.56% | -43.95% | -136.55% |
| EBITDA | 89.22% | -8.13% | -45.64% | -44.34% | -138.09% |
| EPS Basic | 89.44% | -83.67% | -6.60% | -224.77% | -409.52% |
| Normalized Basic EPS | 89.40% | -83.72% | -6.58% | -224.73% | -289.62% |
| EPS Diluted | 89.44% | -83.67% | -4.64% | -227.22% | -434.29% |
| Normalized Diluted EPS | 89.40% | -83.72% | -6.58% | -225.60% | -291.36% |
| Average Basic Shares Outstanding | 0.24% | 0.02% | 0.05% | 96.24% | 205.01% |
| Average Diluted Shares Outstanding | 0.24% | 0.02% | 0.05% | 94.93% | 202.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |